Pneumonia prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(/* Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. {{cite journal |author=Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC...)
Line 16: Line 16:
* When an influenza outbreak is occurring, medications such as [[amantadine]], [[rimantadine]], [[zanamivir]], and [[oseltamivir]] can help prevent influenza.<ref name=jefferson>Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults.''Cochrane Database Syst Rev.'' 2004;(3):CD001169. PMID 15266442</ref><sup>,</sup><ref name=hayden>Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.'' N Engl J Med'' 1999;341:1336–1343PMID 10536125</ref>
* When an influenza outbreak is occurring, medications such as [[amantadine]], [[rimantadine]], [[zanamivir]], and [[oseltamivir]] can help prevent influenza.<ref name=jefferson>Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults.''Cochrane Database Syst Rev.'' 2004;(3):CD001169. PMID 15266442</ref><sup>,</sup><ref name=hayden>Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.'' N Engl J Med'' 1999;341:1336–1343PMID 10536125</ref>


==Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. <ref name="pmid17278083">{{cite journal |author=Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |journal=[[Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America]] |volume=44 Suppl 2 |issue= |pages=S27–72 |year=2007 |month=March |pmid=17278083 |doi=10.1086/511159 |url=http://www.cid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17278083 |accessdate=2012-09-06}}</ref> (DO NOT EDIT)==
{| style="border: 0px; font-size: 85%; margin: 3px; width:900px;" align=center
|valign=top|
|+
! style="background: #4479BA; color:#FFF;  width: 200px;" | Vaccine
! style="background: #4479BA; color:#FFF;  width: 200px;" | Route of Administration
! style="background: #4479BA; color:#FFF;  width: 200px;" | Type of Vaccine
! style="background: #4479BA; color:#FFF;  width: 200px;" | Recommended Groups 
! style="background: #4479BA; color:#FFF;  width: 200px;" | Specific high-risk indications for vaccination
! style="background: #4479BA; color:#FFF;  width: 200px;" | Re-vaccination schedule
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Pneumococcal Vaccine
| style="padding: 5px 5px; background: #F5F5F5;" |Intramuscular injection
| style="padding: 5px 5px; background: #F5F5F5;" |Pneumococcal polysaccharide vaccine
| style="padding: 5px 5px; background: #F5F5F5;" |All persons > 65 years of age, high-risk persons 2–64 years of age, current smokers
| style="padding: 5px 5px; background: #F5F5F5;" |Chronic [[cardiovascular]], [[pulmonary]], [[renal]], or [[liver disease]], [[diabetes mellitus]], cerebrospinal fluid leaks, [[alcoholism]], [[asplenia]], immunocompromising conditions/medications, native Americans and Alaska natives, long-term care facility residents Residence
| style="padding: 5px 5px; background: #F5F5F5;" | One-time revaccination after 5 years for:
*Adults > 65 years of age, if the first dose is received before age 65 years
*Persons with asplenia
*Immunocompromised persons.
 
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | 
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | 
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
 
| style="padding: 0px 5px; background: #F5F5F5;" colspan=5|<small> Adapted from IDSA/ATS Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. <ref name="pmid17278083">{{cite journal |author=Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |journal=[[Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America]] |volume=44 Suppl 2 |issue= |pages=S27–72 |year=2007 |month=March |pmid=17278083 |doi=10.1086/511159 |url=http://www.cid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17278083 |accessdate=2012-09-06}}</ref> </small>
|}
 
 
 
==Infectious Diseases Society of America/American Thoracic Society  (DO NOT EDIT)==
{{cquote|
{{cquote|
===Pneumococcal Vaccine===
======
* '''Route of administration''' - Intramuscular injection
* '''Route of administration''' -  
* '''Type of vaccine''' - Pneumococcal polysaccharide vaccine
* '''Type of vaccine''' -  
* '''Recommended groups''' - All persons > 65 years of age, high-risk persons 2–64 years of age, current smokers
* '''Recommended groups''' -  
* '''Specific high-risk indications for vaccination''' - Chronic [[cardiovascular]], [[pulmonary]], [[renal]], or [[liver disease]], [[diabetes mellitus]], cerebrospinal fluid leaks, [[alcoholism]], [[asplenia]], immunocompromising conditions/medications, native Americans and Alaska natives, long-term care facility residents Residence
* '''Specific high-risk indications for vaccination''' -  
* '''Revaccination schedule''' - One-time revaccination after 5 years for (1) adults > 65 years of age, if the first dose is received before age 65 years; (2) persons with asplenia; and (3) immunocompromised persons.
* '''Re-vaccination schedule''' -  
===Inactivated influenza vaccine===
===Inactivated influenza vaccine===
* '''Route of administration''' - Intramuscular injection
* '''Route of administration''' - Intramuscular injection
Line 37: Line 78:
* '''Specific high-risk indications for vaccination''' - Avoid in high-risk persons
* '''Specific high-risk indications for vaccination''' - Avoid in high-risk persons
}}
}}
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 21:27, 8 December 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]

Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Diagnostic Algorithm

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumonia prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pneumonia prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumonia prevention

CDC onPneumonia prevention

Pneumonia prevention in the news

Blogs on Pneumonia prevention

Directions to Hospitals Treating Pneumonia

Risk calculators and risk factors for Pneumonia prevention

Overview

There are several ways to prevent infectious pneumonia. Appropriately treating underlying illnesses (such as AIDS), smoking cessation, vaccination against pneumococcal, and influenza are the commonly used methods.

Prevention

General Considerations

  • There are several ways to prevent infectious pneumonia. Appropriately treating underlying illnesses (such as AIDS) can decrease a person's risk of pneumonia.
  • Smoking cessation is important not only because it helps to limit lung damage, but also because cigarette smoke interferes with many of the body's natural defenses against pneumonia.
  • Research shows that there are several ways to prevent pneumonia in newborn infants. Testing pregnant women for Group B Streptococcus and chlamydia trachomatis, and then giving antibiotic treatment if needed, reduces pneumonia in infants. Suctioning the mouth and throat of infants with meconium-stained amniotic fluid decreases the rate of aspiration pneumonia.
  • Vaccination is important for preventing pneumonia in both children and adults. Vaccinations against haemophilus influenzae and streptococcus pneumoniae in the first year of life have greatly reduced their role in pneumonia in children.
  • Vaccinating children against streptococcus pneumoniae has also led to a decreased incidence of these infections in adults because many adults acquire infections from children. A vaccine against streptococcus pneumoniae is also available for adults. [1]. Influenza vaccines should be given yearly to the same individuals who receive vaccination against streptococcus pneumoniae. In addition, health care workers, nursing home residents, and pregnant women should receive the vaccine.[2]
  • When an influenza outbreak is occurring, medications such as amantadine, rimantadine, zanamivir, and oseltamivir can help prevent influenza.[3],[4]
Vaccine Route of Administration Type of Vaccine Recommended Groups Specific high-risk indications for vaccination Re-vaccination schedule
Pneumococcal Vaccine Intramuscular injection Pneumococcal polysaccharide vaccine All persons > 65 years of age, high-risk persons 2–64 years of age, current smokers Chronic cardiovascular, pulmonary, renal, or liver disease, diabetes mellitus, cerebrospinal fluid leaks, alcoholism, asplenia, immunocompromising conditions/medications, native Americans and Alaska natives, long-term care facility residents Residence One-time revaccination after 5 years for:
  • Adults > 65 years of age, if the first dose is received before age 65 years
  • Persons with asplenia
  • Immunocompromised persons.
Adapted from IDSA/ATS Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. [5]


Infectious Diseases Society of America/American Thoracic Society (DO NOT EDIT)

“

==

  • Route of administration -
  • Type of vaccine -
  • Recommended groups -
  • Specific high-risk indications for vaccination -
  • Re-vaccination schedule -

Inactivated influenza vaccine

  • Route of administration - Intramuscular injection
  • Type of vaccine - killed virus
  • Recommended groups - All persons > 50 years of age, High-risk persons 6 months–49 years of age, household contacts of high-risk

persons, health care providers, children 6–23 months of age

  • Specific high-risk indications for vaccination -Chronic cardiovascular or pulmonary disease (including asthma), Chronic metabolic disease (including diabetes mellitus), Renal dysfunction, Hemoglobinopathies, Immunocompromising conditions/medications, Compromised respiratory function or increased aspiration risk, pregnancy, aspirin therapy in persons < 18 years of age
  • Revaccination schedule - Annual revaccination

Live Attenuated Influenza Vaccine

  • Route of administration - Intranasal spray
  • Type of vaccine - Live virus
  • Recommended groups - Healthy persons 5–49 years of age,a including health care providers and household contacts of high-risk persons
  • Specific high-risk indications for vaccination - Avoid in high-risk persons
 ”

References

  1. ↑ Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826–1831. PMID 8411526
  2. ↑ Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(RR-4):1–28. PMID 10366138.
  3. ↑ Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults.Cochrane Database Syst Rev. 2004;(3):CD001169. PMID 15266442
  4. ↑ Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336–1343PMID 10536125
  5. ↑ Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083. Retrieved 2012-09-06. Unknown parameter |month= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Pneumonia_prevention&oldid=1046024"